Status:
UNKNOWN
Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation
Lead Sponsor:
Zahra Rabbani Khah
Collaborating Sponsors:
Shahid Beheshti University of Medical Sciences
Conditions:
Hypertensive Phase
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The AGV implant is designed to open when the IOP is between 8 mmHg and 10 mmHg, and thus maintains an IOP of 8 mmHg or higher. In the early period after glaucoma drainage device (GDD) surgery the intr...
Eligibility Criteria
Inclusion
- patients with uncontrolled glaucoma requiring AGV device implantation.
Exclusion
- History of AGV implantation
- Allergy to Anti glaucoma medication
- unable to come for follow up
- Known contraindication to beta blacker such as asthma- chronic obstructive pulmonary disease (COPD). Heart failure heart block
- Learning difficulty- mental illness or severely ill
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT01814514
Start Date
January 1 2011
Last Update
March 20 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Labbafinejad medical center
Tehran, Iran